Silver Book Fact

Flu vaccine use reduces disease burden

Use of the LAIV (live attenuated influenza virus) in healthy adults ages 18 to 64 reduced febrile illness by 19% and upper respiratory tract illnesses by 24%. It also reduced the days of illness by 23% to 27% depending on severity of illness, lost work days by 18% to 28%, and days with visits to health care professionals by 25% to 41%.

Nichol, Kristin L., April Lind, Karen L. Margolis, Maureen Murdoch, Rodney McFadden, et al. The Effectiveness of Vaccination Against Influenza in Healthy, Working Adults. NEJM. 1995; 333(14): 889-93. http://www.nejm.org/doi/full/10.1056/NEJM199510053331401

Reference

Title
The Effectiveness of Vaccination Against Influenza in Healthy, Working Adults
Publication
NEJM
Publication Date
1995
Authors
Nichol, Kristin L., April Lind, Karen L. Margolis, Maureen Murdoch, Rodney McFadden, et al.
Volume & Issue
Volume 333, Issue 14
Pages
889-93
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • Cost-effectiveness of flu vaccine
    Vaccination for pandemic influenza (pH1N1) prior to an outbreak produces incremental cost-effectiveness ratios for individuals without high risk conditions, ranging from $8,000 to $52,000 per quality-adjusted life year.  
  • Drastic reduction of morbidity from vaccine-preventable disease in 20th century
    In the 20th century, vaccines have reduced the morbidity from vaccine-preventable diseases by as much as 89–100%.  
  • An antibiotic stewardship program saved $17 million over 8 years
    An antibiotic stewardship program saved a total of $17 million over 8 years, with antibiotic costs rising $1 million in the first year after discontinuation.  
  • Annual flu vaccine could save 275,000 QALYs
    Offering the influenza vaccine annually to all people over the age of 50 would save around 275,000 quality-adjusted life years over the lifetimes of a birth cohort of 4 million.…  
  • Effectiveness of pneumonia vaccine
    PPSV23 (pneumococcal polysaccharide vaccine) protects against 23 types of pneumococcal bacteria and is 60% to 80% effective in preventing pneumococcal bacteremia in adults over the age of 65 who are…